{"entity":"amgen","id":"ent_amgen","name":"Amgen","from":"2025-11-08","to":"2026-11-08","page":"https://asof.is/record/amgen/diff?from=2025-11-08&to=2026-11-08","summary":"Between 2025-11-08 and 2026-11-08, Amgen's record changed in 17 facts: 3 replaced (net income $4.09 billion → $7.71 billion; operating income $7.26 billion → $9.08 billion; revenue $33.42 billion → $36.75 billion), 7 added, 7 ended; 11 unchanged.","counts":{"changed":17,"added":7,"ended":7,"replaced":3,"unchanged":11,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_operating_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"chair","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"website","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"x_username","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_682A30955369","predicate":"cash_and_equivalents","value":"13,190,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 13,190,000,000 United States dollar\", as of 2026-09-30. Claim clm_682A30955369, https://asof.is/claim/clm_682A30955369, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_682A30955369","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_92C83000279C","predicate":"quarterly_net_income","value":"3,864,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 3,864,000,000 United States dollar\", as of 2026-09-30. Claim clm_92C83000279C, https://asof.is/claim/clm_92C83000279C, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_92C83000279C","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_B7EB0BB6DBEB","predicate":"quarterly_operating_income","value":"3,710,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 3,710,000,000 United States dollar\", as of 2026-09-30. Claim clm_B7EB0BB6DBEB, https://asof.is/claim/clm_B7EB0BB6DBEB, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_B7EB0BB6DBEB","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_985DF46177C9","predicate":"quarterly_revenue","value":"10,365,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 10,365,000,000 United States dollar\", as of 2026-09-30. Claim clm_985DF46177C9, https://asof.is/claim/clm_985DF46177C9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_985DF46177C9","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_E74CF4B58FED","predicate":"shares_outstanding","value":"540,911,490 shares","valid_from":"2026-10-29","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 540,911,490 shares\", as of 2026-10-29. Claim clm_E74CF4B58FED, https://asof.is/claim/clm_E74CF4B58FED, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_E74CF4B58FED","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_8D59A495A2F7","predicate":"total_assets","value":"96,048,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 96,048,000,000 United States dollar\", as of 2026-09-30. Claim clm_8D59A495A2F7, https://asof.is/claim/clm_8D59A495A2F7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_8D59A495A2F7","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_1845D943407A","predicate":"total_equity","value":"14,352,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 14,352,000,000 United States dollar\", as of 2026-09-30. Claim clm_1845D943407A, https://asof.is/claim/clm_1845D943407A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm.","url":"https://asof.is/claim/clm_1845D943407A","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/0000318154-26-000155-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-04"}}],"ended":[{"id":"clm_8E5607E4B59B","predicate":"cash_and_equivalents","value":"9,445,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen cash and equivalents: 9,445,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_8E5607E4B59B, https://asof.is/claim/clm_8E5607E4B59B, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_8E5607E4B59B","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F9355A194FAC","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_E7FF81925833","predicate":"quarterly_net_income","value":"3,216,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly net income: 3,216,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_E7FF81925833, https://asof.is/claim/clm_E7FF81925833, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_E7FF81925833","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_B9855476A1FF","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_A957F605C563","predicate":"quarterly_operating_income","value":"2,526,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly operating income: 2,526,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_A957F605C563, https://asof.is/claim/clm_A957F605C563, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_A957F605C563","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_8FA61AE28EA3","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_56EFD8BFD444","predicate":"quarterly_revenue","value":"9,557,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen quarterly revenue: 9,557,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_56EFD8BFD444, https://asof.is/claim/clm_56EFD8BFD444, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_56EFD8BFD444","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_BA3B03AF2A85","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_2EA05ED8BE57","predicate":"shares_outstanding","value":"538,480,671 shares","valid_from":"2025-10-30","valid_to":"2026-02-10","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen shares outstanding: 538,480,671 shares\", as of 2025-10-30 (until 2026-02-10). Claim clm_2EA05ED8BE57, https://asof.is/claim/clm_2EA05ED8BE57, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_2EA05ED8BE57","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_231B73F793B2","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_A3A1C9D984F8","predicate":"total_assets","value":"90,141,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total assets: 90,141,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_A3A1C9D984F8, https://asof.is/claim/clm_A3A1C9D984F8, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_A3A1C9D984F8","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_D061D89A7312","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-05"}},{"id":"clm_25EEFB9574DF","predicate":"total_equity","value":"9,619,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen total equity: 9,619,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_25EEFB9574DF, https://asof.is/claim/clm_25EEFB9574DF, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm.","url":"https://asof.is/claim/clm_25EEFB9574DF","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_DEE8552AC913","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000072/0000318154-25-000072-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-11-05T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-05"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_ED179BBDEBC9","predicate":"net_income","value":"4,090,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 4,090,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_ED179BBDEBC9, https://asof.is/claim/clm_ED179BBDEBC9, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_ED179BBDEBC9","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_70EECF48CD48","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-14"}},"to":{"id":"clm_70EECF48CD48","predicate":"net_income","value":"7,711,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen net income: 7,711,000,000 United States dollar\", as of 2025-12-31. Claim clm_70EECF48CD48, https://asof.is/claim/clm_70EECF48CD48, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_70EECF48CD48","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-13"}}},{"predicate":"operating_income","from":{"id":"clm_14D79C128253","predicate":"operating_income","value":"7,258,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 7,258,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_14D79C128253, https://asof.is/claim/clm_14D79C128253, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_14D79C128253","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_92AC0DE5846F","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-14"}},"to":{"id":"clm_92AC0DE5846F","predicate":"operating_income","value":"9,080,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen operating income: 9,080,000,000 United States dollar\", as of 2025-12-31. Claim clm_92AC0DE5846F, https://asof.is/claim/clm_92AC0DE5846F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_92AC0DE5846F","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-13"}}},{"predicate":"revenue","from":{"id":"clm_F31DA2CA4F3F","predicate":"revenue","value":"33,424,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-14","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 33,424,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_F31DA2CA4F3F, https://asof.is/claim/clm_F31DA2CA4F3F, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm.","url":"https://asof.is/claim/clm_F31DA2CA4F3F","accessed":"2026-11-08"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_3DD4895A6205","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/0000318154-25-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-14T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-14"}},"to":{"id":"clm_3DD4895A6205","predicate":"revenue","value":"36,751,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Amgen revenue: 36,751,000,000 United States dollar\", as of 2025-12-31. Claim clm_3DD4895A6205, https://asof.is/claim/clm_3DD4895A6205, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm.","url":"https://asof.is/claim/clm_3DD4895A6205","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/0000318154-26-000010-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-13T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-13"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}